Literature review

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Retrieved on: 
Tuesday, February 6, 2024
ICU, Diuretic, Mount Sinai Hospital, Patient, Cirrhosis, Ascites, FDA, Peritoneal cavity, Aquapheresis, Literature review, Food, Blood, Paracentesis, Series, Liver disease, Blood volume, Medical imaging

The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .

Key Points: 
  • The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .
  • The most common cause of liver disease was alcohol-related, with nine of the 14 patients presenting with alcohol-associated cirrhosis.
  • In this case series, Aquadex was shown to provide a potential additional solution to mitigate these clinical gaps.
  • Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics.

Bionl.AI Launches Innovative Platform for No-Code Biomedical Research

Retrieved on: 
Tuesday, October 10, 2023
Literature review, Biomedical Research, Doctor of Philosophy, Student, Natural language processing, GDPR, HIPAA, Communication, Data analysis, ISO27001, Biotechnology, Artificial intelligence, Enterprise, NLP, Master's degree, Natural language, Research

Bionl launches a revolutionary no-code biomedical research platform, transforming scientific exploration

Key Points: 
  • Boston, Massachusetts--(Newsfile Corp. - October 10, 2023) - Bionl , a pioneer in biomedical and bioinformatics research, is honored to announce its official launch.
  • Bionl seeks to revolutionize scientific research by providing a platform that enables researchers, students, and professionals to investigate biomedicine using natural language queries.
  • This revolutionary solution addresses significant challenges in healthcare science by making research quicker, more accessible, and requiring no extensive programming expertise.
  • Bionl.ai is an advanced platform for rapid biomedical research that capitalizes on the most recent developments in natural language processing and artificial intelligence.

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection)

Retrieved on: 
Tuesday, October 10, 2023
Narrative, RA, Adrenocorticotropic hormone, Health, Literature review, Food, Polymyositis, Dermatomyositis, MS, Abstract, Autoimmunity, Length of stay, Spasm, Clinical, Manuscript, Copyright in Historical Perspective, MOA, Nephrotic syndrome, Rheumatoid arthritis, FDA, Proteinuria, RCI, Patient, ClinicoEconomics and Outcomes Research, History, Literature, Lupus, Multiple sclerosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sarcoidosis, Outcomes research, Inflammation, SLE, Pharmaceutical industry, Medical device, Mallinckrodt, Adrenocorticotropic hormone (medication)

DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced the publication of two journal manuscripts reinforcing the clinical and economic evidence supporting the efficacy, safety profile, continued use, and cost-effectiveness of Acthar Gel for appropriate patients across a range of FDA-approved autoimmune and inflammatory disease indications.1,2 

Key Points: 
  • Mallinckrodt's health economics manuscript titled "Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence" was published on June 24, 2023 in ClinicoEconomics and Outcomes Research.
  • Acthar is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides.
  • Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several autoimmune disorders and medical conditions known to cause inflammation.3
    Please see indications and Important Safety Information below.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical outcomes may not be solely attributable to Acthar.

Study Reveals Prolacta's 100% Human Milk-Based Nutritional Fortifiers Significantly Increase Bioactive Proteins and Antioxidant Activity in Human Milk Samples, Outperforming Cow Milk-Based Fortifier

Retrieved on: 
Monday, June 12, 2023
Hospice and palliative medicine, Breastfeeding Support for Indian Mothers, University, Immunity, Literature review, MBA, DHM, Milk, MOM, MD, Lactoferrin, University of Limerick, Dairy, Growth

DUARTE, Calif., June 12, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today announced that Breastfeeding Medicine has published an independent study demonstrating Prolacta's human milk-based fortifiers (HMBF) reinstate and significantly boost bioactive proteins when added to mother's own milk (MOM) and donor human milk (DHM).1 The naturally occurring bioactive components in human milk are thought to support infants' immunity, development, growth, and long-term health.2

Key Points: 
  • It was authored by Professor Roy K. Philip, MD, MBA, and colleagues of the University of Limerick School of Medicine, and Bernal Institute, University of Limerick, Ireland.
  • "Pasteurized donor human milk showed significantly low bioactive properties in comparison to fresh and frozen MOM; however, the addition of HMBF reinstated and further enhanced bioactivity to partially offset the effects of pasteurization.
  • "1
    The study found milk samples fortified with Prolacta's HMBF contained higher protein, fat, and total solids (p
  • "3-16
    On June 27, Professor Philip will present his study findings in a webinar titled Exclusive Human Milk Diet (EHMD) for Extremely Premature Infants: a Fortification Strategy to Enhance Bioactivity.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Abstract, EASL, Therapy, NASH, NAS, ISPOR, Obeticholic acid, NDA, Research, Non-alcoholic fatty liver disease, Meta-analysis, Different, Literature review, Breakthrough therapy, Evidence, Patient, Term Asset-Backed Securities Loan Facility, Institute for Clinical and Economic Review, Fibrosis, NHANES, Prevalence, ICER, Liver, Fatty liver disease, Loan, FDA, Epidemiology, Three Months, Treatment, Cirrhosis, Pharmaceutical industry, Medical imaging, Dietary supplement, Inflammation, Madrigal, Lipid

Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial

Key Points: 
  • Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial
    CONSHOHOCKEN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports first quarter 2023 financial results.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “In the first quarter of 2023, the Madrigal team made significant progress advancing our regulatory preparations, disease education initiatives, and market access strategy.
  • Additionally, we continue to execute against our clinical development objectives, and have completed enrollment of the MAESTRO-NASH trial.
  • Interest expense for the three month period ended March 31, 2023 was $2.3 million, compared to $0.0 million in the comparable prior year period.

CDAHK Chiropractors Pushes Healthy Feeding of Children

Retrieved on: 
Saturday, November 26, 2022
Tao, CRP, NP-hardness, Gingivitis, SIRVA, Bell's palsy, Pain scale, Calisto occulta, Case report, Patient, Metastasis, Diarrhea, Breast milk, Interview, Academy of Family Physicians of India, Foramen magnum, Dizziness, Parkinson's disease, Breast cancer, UNICEF, Health, Deformity, Prostate cancer, Vaccination, COVID-19, Growth, Postural orthostatic tachycardia syndrome, Food, Parent, Literature review, Life, Medical Science Monitor, Low back pain, Research, Pectus carinatum, Global Health, PubMed Central, Multimedia, Mother, Neck pain, Vertebral hemangioma, Pathology, Prevalence, Death, Headache, Streptococcus oralis, Signs and symptoms, PubMed, Abdominal aortic aneurysm, Toy, Birth control, Dietary supplement, Poultry, Renewable energy, Medical device, Online shopping, Chiropractic

LOS ANGELES, Nov. 26, 2022 /PRNewswire/ -- A study in the journal BMJ Global Health found that mothers who were exposed to a lot of digital marketing were less likely to breastfeed their babies for the first six months of their lives and more likely to give them processed foods and sugary drinks.

Key Points: 
  • Chiropractors from the CDAHK say that for your baby's best growth, development, and health, you should only breastfeed him or her for the first six months of life.
  • He received the prestige Effective Outreach Partner Award for the contribution to breastfeeding by the United Nation Children Foundation (UNICEF).
  • The CDAHK's vision and actions always aim at forging business and educating the public about healthy feeding enduring meaning and value that will eventually shape an exceptional future.
  • This call to action is very important to protect children's health and their right to breast milk and natural, healthy, enough, and good food.

Chiropractic May Offer Relief From Complicated Chronic Headaches

Retrieved on: 
Monday, November 21, 2022
Tao, Signs and symptoms, Report, Postural orthostatic tachycardia syndrome, Pathology, Sensation, Neck, Neck pain, Pectus carinatum, Neurofibromatosis, Chronic pain, Pain scale, Lactic acid, History, Chiropractic, Foramen magnum, Spine, ECP, Multimedia, Dizziness, Patient, Head, Executive Committee, Bell's palsy, Radiculopathy, Academy of Family Physicians of India, Literature review, CRP, Dentistry, Poultry, Birth control, Healthcare, Online shopping, Headache

NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Chiropractors may reduce the number of monthly neck pain and headaches for people who have chronic and complicated type of history, four case studies (1-4) published in 2022 American Journal of Case Reports, found.

Key Points: 
  • The researchers from Chiropractic Doctors Association of Hong Kong (CDAHK) released their case studies on chronic headaches and neck pain.
  • Chiropractors provide long-term relief from chronic headaches, said Eric Chu, principal investigator of the studies and Chairman of Chiropractic Doctors Association of Hong Kong.
  • "Our recent studies(4-12) have also found that chiropractic may be effective for episodic neck pain and chronic headaches.
  • Treating chronic pain is a multidisciplinary approach, and chiropractic is one of best treatment options that should be considered," Chu said.

Scientists Identify Hidden Factor That Help Pain after Fibromyalgia

Retrieved on: 
Monday, November 14, 2022
Tao, Gait, Postural orthostatic tachycardia syndrome, Awareness, Pain scale, Association, Grammatical mood, Academy of Family Physicians of India, NP-hardness, Parkinson's disease, Massage, Literature review, Fatigue, Report, Pinealectomy, Spondylosis, Prostate cancer, Neck pain, Pectus carinatum, Metastasis, Posture, Electromyography, Patient, Quality of life, Low back pain, Signs and symptoms, Back pain, Hidden, Multimedia, Dizziness, Diagnosis, Domestic violence, Breast cancer, Sleep, Knee pain, Deformity, Rehabilitation, NEW, Foramen magnum, ECP, American Journal, Thought, Headache, Bell's palsy, Schwannoma, Pharmaceutical industry, Medical device, Poultry, Birth control, Healthcare, Online shopping, Medicine, Fibromyalgia

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Scientists have identified treating cervical spondylosis helps patients with fibromyalgia stand up and live again.

Key Points: 
  • NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Scientists have identified treating cervical spondylosis helps patients with fibromyalgia stand up and live again.
  • A woman presented with a chronic headache, severe neck pain, shoulder pain, and back pain lasting for 2 years after experiencing domestic violence.
  • The widespread pain in fibromyalgia can lead to confused thinking and a lack of awareness of cervical spondylosis.
  • According to the researchers, this suggests chiropractic treatment blocked noxious inputs coming from pain sources, corrected pain thresholds, and lowered excitability, thereby eradicating fibromyalgia symptoms.

Relievant Medsystems Announces Updated Policy Statement and Guideline for Basivertebral Nerve Ablation from the International Society for the Advancement of Spine Surgery

Retrieved on: 
Tuesday, November 8, 2022
Quality of life, GLOBE, Vertebra, International Society, Adoption, Society, Diagnosis, ASPN, BVN, Brain, Literature review, Patient, Canadian International Council, Time, Policy, Inflammation, Awareness, Pain, Treatment, CEO, Intraosseous infusion, FDA, Dentistry, Neuroscience

The ISASS policy recommends intraosseous BVN ablation as the most successful way to address vertebrogenic chronic low back pain.

Key Points: 
  • The ISASS policy recommends intraosseous BVN ablation as the most successful way to address vertebrogenic chronic low back pain.
  • This update follows the September publication of Best Practice Guidelines on the Diagnosis and Treatment of Vertebrogenic Low Back Pain with BVN Ablation from the American Society of Pain and Neuroscience (ASPN) and demonstrates additional society support for BVN ablation.
  • Relievant Medsystems minimally invasive Intracept Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain.
  • For more information about Relievant Medsystems and the Intracept Procedure, visit www.relievant.com .

Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera

Retrieved on: 
Thursday, November 3, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Fumaric acid, Private Securities Litigation Reform Act, Research, PV, Bone marrow, Embolism, Risk, EMA, Biotechnology, European Medicines Agency, Boxed warning, Legislation, Literature review, Essential, Interferon alfa-2b, Hematology, Polycythemia, Polycythemia vera, Fibrosis, Thrombosis, News, Leukemia, Patient, Cancer, Vaccine, Pharmaceutical industry, Incidence

Follow PharmaEssentia USA on Twitter and LinkedIn to get news and updates on our activity at the ASH Annual Meeting.

Key Points: 
  • Follow PharmaEssentia USA on Twitter and LinkedIn to get news and updates on our activity at the ASH Annual Meeting.
  • PV may result in cardiovascular complications such as thrombosis and embolism, and often transforms to secondary myelofibrosis or leukemia.
  • BESREMi has orphan drug designation for treatment of polycythemia vera (PV) in adults in the United States.
  • Blast Transformation and Fibrotic Progression in Polycythemia Vera and Essential Thrombocythemia: A Literature Review of Incidence and Risk Factors.